Results 141 to 150 of about 46,339 (291)

Perioperative Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide (NT- proBNP) Level in Patients Undergoing Open Heart Surgery [PDF]

, 2019
Mohamed Hamed, M.D. EL-HADY M. TAHA EL-ATAFY E. EL-ATAFY   +1 more
openalex   +1 more source

Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study

ESC Heart Failure, Volume 12, Issue 2, Page 1326-1335, April 2025.
Abstract Aims Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart failure (HF) with preserved or reduced ejection fraction.
Robin Willixhofer, Mauro Contini, Michele Emdin, Damiano Magrì, Alice Bonomi, Elisabetta Salvioni, Fabrizio Celeste, Alberico Del Torto, Claudio Passino, Christophe D.J. Capelle, Chiara Arzilli, Emiliano Fiori, Nicolò Capra, Christina Kronberger, Nikita Ermolaev, Andreas Kammerlander, Beatrice Musumeci, Giuseppe Vergaro, Vincenzo Castiglione, René Rettl, Giacomo Tini, Andrea Baggiano, Iacopo Fabiani, Susanna Sciomer, Roza Badr Eslam, Piergiuseppe Agostoni   +25 more
wiley   +1 more source

Sodium‐Glucose Cotransporter 2 Inhibitors for Mesenchymal–Epithelial Transition Inhibitor‐Induced Edema

Thoracic Cancer
The effects of sodium‐glucose cotransporter 2 (SGLT2) inhibitors on mesenchymal‐epithelial transition factor (MET) inhibitor‐induced edema remain unclear. In a patient with tepotinib‐induced edema and an N‐terminal pro‐brain natriuretic peptide (NTproBNP)
Takuya Oyakawa, Keita Miura, Nao Muraoka, Kei Iida, Ayano Fujita, Tateaki Naito, Toshiaki Takahashi   +6 more
doaj   +1 more source

Normal range of N-terminal pro-brain natriuretic peptide: a note of caution [PDF]

, 2006
Thomas Wölber
openalex   +1 more source

N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE LEVELS IN PATIENTS WITH EARLY AND LONG-TERM RHEUMATOID ARTHRITIS [PDF]

, 2021
Liubov Kondrateva, T. A. Panafidina, Т. В. Попкова, Е. В. Герасимова, Yulia Gorbunova   +4 more
openalex   +1 more source

The use of cardiac biomarkers in veterinary medicine: the equine perspective [PDF]

, 2012
In human medicine, cardiac biomarkers, such as natriuretic peptides and troponins, are routinely used for the diagnosis, prognosis and monitoring of heart diseases.
De Clercq, Dominique, Decloedt, Annelies, Van Der Vekens, Nicky, van Loon, Gunther, Verheyen, Tinne   +4 more
core   +1 more source

SPARCL1 and NT‐proBNP as biomarkers of right ventricular‐to‐pulmonary artery uncoupling in pulmonary hypertension

ESC Heart Failure, Volume 12, Issue 2, Page 1416-1426, April 2025.
Abstract Aims SPARCL1 was recently identified as a biomarker of right ventricular (RV) maladaptation in patients with pulmonary hypertension (PH), and N‐terminal pro‐brain natriuretic protein (NT‐proBNP) is an established biomarker of RV failure in PH. The present study investigated whether NT‐proBNP and SPARCL1 concentrations are associated with load ...
Oliver Dörr, Stanislav Keranov, Paulina van Wickern, Holger Nef, Christian Hamm, Pascal Bauer, Christian Troidl, Samuel Sossalla, Sandra Voss, Christoph Liebetrau, Manuel J. Richter, Henning Gall, Werner Seeger, Ardeschir Ghofrani, Athiththan Yogeswaran, Khodr Tello   +15 more
wiley   +1 more source

Long-Term Pattern of Brain Natriuretic Peptide and N-Terminal Pro Brain Natriuretic Peptide and Its Determinants in the General Population: Contribution of Age, Gender, and Cardiac and Extra-Cardiac Factors [PDF]

, 2013
Andreas Luchner, Gundula Behrens, Jan Stritzke, Marcello Ricardo Paulista Markus, Klaus Stark, Annette Peters, Christa Meisinger, Michael F. Leitzmann, Hans‐Werner Hense, Heribert Schunkert, Iris M. Heid   +10 more
openalex   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

MiR‐145‐5p Attenuates Doxorubicin‐Induced Heart Injury Through Targeting Cardiomyocyte Pyroptosis

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Doxorubicin (DOX), a potent anthracycline chemotherapeutic, exhibits dose‐dependent cardiotoxicity that limits its clinical utility. Although miR‐145‐5p demonstrates cardioprotective properties in cardiovascular diseases, its role in DOX‐induced cardiomyopathy remains undefined.
Xing‐Tao Chen, Yong‐Hong Yu, Yan‐Hua Du, Lin Xu, Xiang‐Ping Meng   +4 more
wiley   +1 more source